Genelux Corp SEC Filings

Genelux Corporation president and CEO Thomas Zindrick reported sales of company common stock primarily to cover estimated taxes related to the vesting of restricted stock units. On August 21, 2025, he sold 12,673 shares of common stock at an average price of $3.3267 per share, and on November 17, 2025 he sold an additional 4,509 shares at $5.3694 per share.

After these transactions, he beneficially owned 538,431 shares of Genelux common stock directly. According to the footnotes, this total reflects the reported sales, transactions reported on a filing dated August 29, 2025, and 1,452 shares acquired under the Issuer's Employee Stock Purchase Plan on November 14, 2025.

Genelux Corporation (GNLX) filed its Q3 2025 10‑Q, reporting continued operating losses and a going concern warning. Net loss was $7.95 million for the quarter and $22.9 million for the nine months ended September 30, 2025, as the company recorded $8.2 million in quarterly operating expenses driven by R&D and G&A.

Liquidity remains constrained: cash, cash equivalents, restricted cash and short‑term investments totaled $21.0 million as of September 30, 2025, and net cash used in operations was $19.1 million for the nine months. Management states these resources are expected to fund operations into the third quarter of 2026. The independent auditor previously expressed substantial doubt about the company’s ability to continue as a going concern.

Genelux completed a March 2025 underwritten offering of 3,000,000 shares at $3.50, yielding $9.6 million in net proceeds, and issued an underwriter warrant for 120,000 shares at $4.20. Shares outstanding were 38,046,778 as of September 30, 2025. The company continues advancing Olvi‑Vec, including a Phase 2 NSCLC trial under its Newsoara collaboration.

Genelux Corporation (GNLX) insider reported changes to outstanding stock options held by President and CEO Thomas Zindrick. On 09/01/2025 the exercise prices of multiple option grants were reduced to $3.33 per share, the companys common stock price on that date. The filing shows corresponding dispositions of the original higher-priced options and contemporaneous grants at the lower exercise price across option series exercisable through 2033. The filing states there was no change to expiration dates or vesting schedules and that affected awards are fully vested where noted. The report is signed by Mr. Zindrick on 09/03/2025.

Genelux Corporation insider filing reports that Yu Yong, SVP, Clinical Development and director, had multiple stock options repriced effective September 1, 2025. Two option grants were adjusted so the exercise price was reduced to $3.33 per share (from prior prices of $6.00 and $22.40). The filing shows a one-time reduction only; expiration dates and vesting schedules were unchanged. After the reported transactions, Mr. Yu beneficially owns 207,652 shares underlying one repriced option and 65,000 shares underlying another option, with both grants showing vested or scheduled vesting as described.

Genelux Corp (GNLX) reporting person Ralph Smalling received 10,000 restricted stock units that vest over time and had option activity effective 09/01/2025. The RSUs vest 25% after one year and then in 12 equal quarterly installments. An existing option for 8,333 shares with a $6.00 exercise price was replaced by an option covering 8,333 shares with a reduced exercise price of $3.33 effective 09/01/2025; vesting and expiration (09/23/2030) remain unchanged. Following the transactions, Mr. Smalling beneficially owned 70,990 shares and held 8,333 exercisable options.

Genelux Corporation director and Chief Technical Officer Joseph Cappello reported a series of option transactions dated 09/01/2025. The filing shows a one-time reduction of option exercise prices effective that date: several stock options previously priced at $6.00 and $22.40 were reduced to an exercise price of $3.33, described as the issuer's common stock price on September 1, 2025. The filing records both dispositions (D) of the higher-priced options and acquisitions (A) of replacement options at $3.33, with no changes to expiration dates or vesting schedules. The filing notes that the shares subject to these options are fully vested for some grants and specifies vesting terms for others.

Genelux Corporation director John Thomas reported equity awards on 08/27/2025. The Form 4 shows a grant of 22,283 restricted stock units (RSUs) and an acquisition of 28,576 stock options with an exercise price of $3.64 and an expiration date of 08/26/2035. Following the reported RSU grant, Mr. Thomas beneficially owns 502,784 shares.

The RSUs and options vest upon the earlier of the one-year anniversary of grant or the issuer's next annual meeting of stockholders. Both the RSUs and the options are reported at $0 consideration for the RSUs and an exercise price of $3.64 for the options.

Genelux Corporation insider report: Thomas Zindrick, the company's President and CEO and a director, received equity awards that increase his potential ownership. He was granted 361,200 restricted stock units (RSUs) that convert to common shares upon vesting and a stock option covering 478,800 shares with an exercise price of $3.64. After the reported transactions, he beneficially owns 554,161 shares of common stock (including 1,514 shares from the Employee Stock Purchase Plan) and holds options exercisable into 478,800 shares. The RSUs vest 25% after one year, then quarterly over the remainder; the option vests 25% after one year, then monthly over the remainder, and expires in 2035.